Immunoinformatic Execution and Design of an Anti-Epstein–Barr Virus Vaccine with Multiple Epitopes Triggering Innate and Adaptive Immune Responses
Authors:
- Naveed AhmedNaveed Ahmed
- Ali A. RabaanARAli A. Rabaan
- Ameen S. S. AlwashmiAAAmeen S. S. Alwashmi
- Hawra AlbayatHAHawra Albayat
- Mutaib M. MashraqiMMMutaib M. Mashraqi
- Ahmad A. AlshehriAAAhmad A. Alshehri
- Mohammed GaroutMGMohammed Garout
- Wesam A. AbduljabbarWAWesam A. Abduljabbar
- Nik Yusnoraini YusofNYNik Yusnoraini Yusof
- Chan Yean YeanChan Yean Yean
Open Access
- 29 September 2023
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 11 (10) , 2448
Abstract
One of the most important breakthroughs in healthcare is the development of vaccines. The life cycle and its gene expression in the numerous virus-associated disorders must be considered when choosing the target vaccine antigen for Epstein–Barr virus (EBV). The vaccine candidate used in the current study will also be effective against all other herpesvirus strains, based on the conservancy study, which verified that the protein is present in all herpesviruses. From the screening, two B-cell epitopes, four MHC-I, and five MHC-II restricted epitopes were chosen for further study. The refined epitopes indicated 70.59% coverage of the population in Malaysia and 93.98% worldwide. After removing the one toxin (PADRE) from the original vaccine design, it was projected that the new vaccine would not be similar to the human host and would instead be antigenic, immunogenic, non-allergenic, and non-toxic. The vaccine construct was stable, thermostable, soluble, and hydrophilic. The immunological simulation projected that the vaccine candidate would be subject to a long-lasting active adaptive response and a short-lived active innate response. With IgM concentrations of up to 450 cells per mm3 and active B-cell concentrations of up to 400 cells per mm3, the B-cells remain active for a considerable time. The construct also discovered other conformational epitopes, improving its ability to stimulate an immune response. This suggests that, upon injection, the epitope will target the B-cell surface receptors and elicit a potent immune response. Furthermore, the discotope analysis confirmed that our conformational B-cell epitope was not displaced during the design. Lastly, the docking complex was stable and exhibited little deformability under heat pressure. These computational results are very encouraging for future testing of our proposed vaccine, which may potentially help in the management and prevention of EBV infections worldwide.Keywords
Funding Information
- Ministry of Higher Education, Malaysia (FRGS/1/2020/SKK0/USM/02/22)
This publication has 36 references indexed in Scilit:
- Reliable B Cell Epitope Predictions: Impacts of Method Development and Improved BenchmarkingPLOS Computational Biology, 2012
- EBV-Specific CD8+ T Cells from Asymptomatic Pediatric Thoracic Transplant Patients Carrying Chronic High EBV Loads Display Contrasting Features: Activated Phenotype and Exhausted FunctionThe Journal of Immunology, 2011
- Epstein-Barr Virus Nuclear Protein 3C Domains Necessary for Lymphoblastoid Cell Growth: Interaction with RBP-Jκ Regulates TCL1Journal of Virology, 2009
- NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding predictionBMC Bioinformatics, 2009
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- ElliPro: a new structure-based tool for the prediction of antibody epitopesBMC Bioinformatics, 2008
- The role of Epstein–Barr virus in cancerExpert Opinion on Biological Therapy, 2006
- Correlation between the location of antigenic sites and the prediction of turns in proteinsImmunology Letters, 1993
- New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and x-ray-derived accessible sitesBiochemistry, 1986
- Prediction of chain flexibility in proteinsThe Science of Nature, 1985